M
Markus Hoffmann
Researcher at German Primate Center
Publications - 155
Citations - 23747
Markus Hoffmann is an academic researcher from German Primate Center. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 30, co-authored 103 publications receiving 14853 citations. Previous affiliations of Markus Hoffmann include University of Veterinary Medicine Hanover & University of Veterinary Medicine Vienna.
Papers
More filters
Journal ArticleDOI
The Upper Respiratory Tract of Felids Is Highly Susceptible to SARS-CoV-2 Infection.
Nadine Krüger,Cheila Rocha,Sandra Runft,Johannes Krüger,Iris Färber,Federico Armando,Eva Leitzen,Graham Brogden,Gisa Gerold,Stefan Pöhlmann,Stefan Pöhlmann,Markus Hoffmann,Markus Hoffmann,Wolfgang Baumgärtner +13 more
TL;DR: In this paper, primary cell cultures derived from the nose, trachea, and lungs of cat and lion were inoculated with SARS-CoV-2, and strong viral replication was observed for nasal mucosa explants and tracheal air-liquid interface cultures.
Journal ArticleDOI
Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5
Journal ArticleDOI
Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
Sebastian R. Schulz,Markus Hoffmann,Edith Roth,Katharina Pracht,Deborah L. Burnett,Ohan Mazigi,Wolfgang Schuh,Bernhard Manger,Dirk Mielenz,Christopher C. Goodnow,Daniel Christ,Stefan Pöhlmann,Hans-Martin Jäck +12 more
TL;DR: There is compelling evidence that the third vaccination with BNT162b2 increases the amount of neutralizing serum antibodies against Delta and Omicron variants, albeit to a lower degree when compared to the parental Wuhan strain.
Journal ArticleDOI
Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy
Markus Hoffmann,Anzhalika Sidarovich,Prerna Arora,Nadine Krüger,Inga Nehlmeier,Amy Kempf,Luise Graichen,Martin Sebastian Winkler,Daniela Niemeyer,Christine Goffinet,Christian Drosten,Sebastian R. Schulz,Hans-Martin Jäck,Stefan Pöhlmann +13 more
TL;DR: It is suggested that the naturally occurring mutation E484D allows SARS-CoV-2 to employ an ACE2-independent mechanism for entry that is largely insensitive against Imdevimab, an antibody employed for COVID-19 therapy.
Journal ArticleDOI
Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19
Kritika Khanna,Wilfred W. Raymond,Jing Jin,Annabelle R. Charbit,Irina Gitlin,Monica Tang,Adam D. Werts,Edward G. Barrett,Jason Cox,Sharla M. Birch,R. Martinelli,Hannah S. Sperber,Sergej Franz,Thomas Duff,Markus Hoffmann,Anne Marie Healy,Stefan Oscarson,Stefan Pöhlmann,Satish K. Pillai,Graham Simmons,John V. Fahy +20 more
TL;DR: Thiol drugs decrease SARS-CoV-2 lung inflammation and injury and it is speculated that the concentration of cysteamine achieved in the lungs with IP delivery was insufficient for antiviral effects but sufficient for anti-inflammatory effects.